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Abstract
Patients infected or colonized with carbapenem-resistant Klebsiella pneumoniae (CRKp) are often 
chronically and acutely ill, which results in substantial mortality unrelated to infection. Therefore, 
estimating excess mortality due to CRKp infections is challenging. The Consortium on Resistance 
against Carbapenems in K. pneumoniae (CRACKLE) is a prospective multicenter study. Here, 
patients in CRACKLE were evaluated at the time of their first CRKp bloodstream infection (BSI), 
pneumonia, or urinary tract infection (UTI). A control cohort of patients with CRKp urinary 
colonization without CRKp infection was constructed. Excess hospital mortality was defined as 
mortality in cases after subtracting mortality in controls. In addition, the adjusted hazard ratios 
(aHR) for time-to-hospital-mortality censored at 30 days associated with infection as compared to 
colonization were calculated in Cox proportional hazard models. In the study period, 260 patients 
with CRKp infections were included in the BSI (90), pneumonia (49), and UTI (121) groups, who 
were compared to 223 controls. All-cause hospital mortality in controls was 12%. Excess hospital 
mortality was 27% and 27% in patients with BSI and pneumonia, respectively. Excess hospital 
mortality was not observed in patients with UTI. In multivariable analyses, BSI and pneumonia as 
compared to controls was associated with an aHR of 2.59 (95% CI 1.52–4.50, p<0.001) and 3.44 
(95% CI 1.80–6.48, p<0.001), respectively. In conclusion, in patients with CRKp infection, 
pneumonia is associated with the highest excess hospital mortality. Patients with BSI have slightly 
lower excess hospital mortality rates, whereas excess hospital mortality was not observed in 
hospitalized patients with UTI.
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 Introduction
Infections with carbapenem-resistant Enterobacteriaceae (CRE) are an important and 
growing threat to vulnerable hospitalized patients [1]. Patients who are at risk for 
colonization and/or infection with CRE during hospitalization tend to be chronically and 
acutely ill [2–4]. Carbapenem-resistant Klebsiella pneumoniae (CRKp) are the most 
common CRE in the United States. Reported estimates of all-cause hospital mortality rates 
of CRKp infection depend on the type of infection [2]. Most data are available for CRKp 
bloodstream infections for which estimates range from ~40 to ~70% [5–11]. For non-
bacteremic CRKp infections, fewer studies specifically report mortality rates. CRKp 
pneumonia was associated with 24% all-cause hospital mortality in a recent US-based report 
and 40% all-cause 14-day mortality in a larger Italian study [11, 12]. Available data suggest 
that CRKp urinary tract infections are associated with only limited mortality [2, 11, 13].
Determining the impact of CRKp infection on mortality in hospitalized patients is 
challenging given the extensive chronic comorbidities which these patients tend to have. 
Moreover, infections with CRKp tend to be associated with various invasive procedures and 
devices during hospitalization, as well as with exposure to intensive care settings. These risk 
factors are independently associated with mortality, even in the absence of infection. 
Therefore, estimating the hospital mortality associated with infection with CRKp is not 
straightforward. The overall mortality of patients who die in the hospital following CRKp 
infection is the sum of infection-related mortality and non-infection-related mortality. This 
non-infection-associated contribution to overall mortality is relatively larger in patients 
colonized with CRKp as compared to patients colonized with more susceptible organisms, 
since risk factors for mortality such as chronic and acute illness, overlap with risk factors for 
CRKp colonization. An estimate of this non-infection-related mortality may be 
approximated in patients who are colonized, but not infected with CRKp. Estimating the 
infection-related mortality by subtracting this non-infection-related mortality is important, 
given the expectation that any intervention geared towards improved treatment of infection 
will only impact that infection-related mortality. Therefore, even a “perfect” antibiotic – i.e. 
a treatment that would reduce infection-related mortality in patients infected with CRKp to 
0% – is expected to only decrease overall hospital mortality to the rate of CRKp colonized 
controls.
In this study, prospectively collected data from the multicenter Consortium on Resistance 
against Carbapenems in Klebsiella pneumoniae (CRACKLE) were analyzed to approximate 
the impact on hospital mortality of specific CRKp infections by comparing the hospital 
mortality rates associated with these infections to those observed in patients colonized but 
not infected with CRKp.
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 Methods
 Design
The Consortium on Resistance against Carbapenems in Klebsiella pneumoniae (CRACKLE) 
was previously described [14, 15]. Briefly, CRACKLE is a multicenter, prospective, 
longitudinal, observational study of hospitalized patients with positive cultures for CRKp. In 
the study period from 12/24/2011 to 10/1/2014, 3 nested case cohorts were constructed from 
patients enrolled in CRACKLE; patients with CRKp bloodstream infection (BSI), CRKp 
pneumonia, and CRKp urinary tract infection (UTI), respectively. A control cohort 
consisting of patients with CRKp urinary colonization was also constructed. In the control 
cohort, patients who previously or subsequently developed CRKp BSI, CRKp pneumonia, 
and/or CRKp UTI were excluded. In all cohorts, patients were included only once at the 
time of the first occurrence of infection or colonization. Routine screening of asymptomatic 
patients for CRKp carriage was not performed at any of the study sites during the study 
period. The Institutional Review Boards of all sites involved approved the study.
 Definitions
Time-to-hospital-mortality was the primary outcome of study. The day of the first positive 
culture for CRKp was used as day 0 for time-to-event analyses. For analysis purposes, 
patients discharged to hospice were considered deceased at the time of discharge. Critical 
illness was defined as a Pitt bacteremia score greater or equal to 4 points, on the day of the 
index culture [16]. Standardized definitions of infections were used, as previously described 
[2, 17]. Briefly, a patient with a blood culture positive for CRKp was deemed to have a 
CRKp BSI. For patients with positive respiratory cultures the criteria outlined by the 
American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) 
were used [18, 19]. Criteria as outlined by Centers for Disease Control/National Healthcare 
Safety Network (CDC/NHSN) were used to define UTI and asymptomatic bacteremic UTI 
(ABUTI); these two categories were grouped together as UTI for analysis purposes [20]. 
Briefly, patients with a positive urine culture for CRKp, who had at least one of the 
following signs or symptoms: fever (>38.0°C), suprapubic tenderness, costovertebral angle 
pain or tenderness, urinary urgency, urinary frequency, or dysuria were considered to have a 
UTI [20]. In addition, ABUTI was defined as having a positive blood and urine culture 
positive for CRKp without urinary symptoms [20]. Patients who had positive urine cultures 
for CRKp, who did not meet criteria for infection per CDC/NHSN were considered to have 
CRKp urinary colonization.
 Microbiology
Any K. pneumoniae isolate with non-susceptibility (MIC > 1 μg/ml) to any tested 
carbapenem was considered a CRKp as per guidelines from the Clinical and Laboratory 
Standards Institute [21]. Bacterial identification and routine antimicrobial susceptibility 
testing was performed with MicroScan (Siemens Healthcare Diagnostics) or Vitek2 
(BioMerieux), supplemented by GN4F Sensititre tray (Thermo Fisher) or Etest 
(bioMerieux), as indicated. In more than 90% of tested isolates, carbapenem resistance was 
mediated through blaKPC-2 or blaKPC-3, as previously described [14].
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 Statistical Analysis
Differences between groups were analyzed using Wilcoxon Rank Sum for continuous 
variables. Modified Wald method was used to calculate 95% confidence intervals for 
proportions. Fisher’s Exact, and Pearson testing were used for categorical variables where 
appropriate. Kaplan-Meier curves were used to compare time-to-hospital-mortality in the 
various cohorts. Cox proportional hazards models on time-to-hospital-mortality was used to 
calculate adjusted hazard ratios (aHR). For time-to-mortality analyses, patients were 
censored at the time of hospital discharge, or if still admitted and alive at 30 days after first 
positive culture, patient data were censored at 30 days after the date of the first positive 
culture. Forward selection was used for inclusion of variables in multivariable Cox 
proportional hazards models; any variable that was associated with time-to-hospital-
mortality at p<0.2 was included. However, if the Charlson comorbidity index was included 
in the multivariable model, components of this score (such as renal failure) were not 
separately included. P values of ≤0.05 were considered statistically significant. JMP 10.0.1 
software (SAS, Inc, Cary, NC) was used for all analyses.
 Results
 Patients
During the study period, 90, 49, and 121 patients had BSI, pneumonia, and UTI, 
respectively. In the control cohort 223 patients with CRKp urinary colonization were 
included (Table 1). Patients with urinary colonization were more likely to be female, and 
tended to be slightly older. No differences were observed in the distribution of comorbid 
conditions, such as diabetes, heart disease and chronic kidney disease.
 Excess mortality
In the BSI cohort, 35/90 (39%) patients died or were discharged to hospice, as compared to 
26/223 (12%) in controls (Table 2). This results in an excess hospital-mortality of CRKp 
BSI of 27% (95% CI 16%–38%). In patients with pneumonia, 19/49 (39%) patients died or 
were discharged to hospice, resulting in excess hospital mortality of CRKp pneumonia of 
27% (95% CI 14%–43%). In contrast, CRKp UTI was not associated with excess mortality 
(estimate −3%, 95% CI −9%–3%).
The time-to-hospital-mortality was compared between each infection cohort and the control 
cohort (Figure 1). BSI and pneumonia were associated with increased hazards of mortality 
(see Tables 3 and 4). In multivariable Cox proportional hazard modeling, the adjusted HR 
(aHR) of BSI and pneumonia were 2.59 (95% CI 1.52–4.50, p<0.001) and 3.44 (95% CI 
1.80–6.48, p<0.001), respectively. UTI was not associated with an increased hazard (aHR 
0.68, 95% CI 0.30–1.45, Table 5). In the models comparing patients with pneumonia and 
controls, as well as the model that compared patients with UTI and their controls, the 
Charlson comorbidity index was associated with time-to-hospital-mortality with an aHR of 
1.19 (95% CI 1.06–1.34, p<0.01), and 1.20 (95% CI 1.06–1.36, p<0.01) per point increase, 
respectively. When comparing BSI and controls, no association between the Charlson 
comorbidity index and mortality was observed (Table 3). To determine the impact of 
grouping patients who were discharged to hospice together with those who died, the Cox 
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models were repeated and patients discharged to hospice were considered “alive”. In these 
models, BSI vs. colonization and pneumonia vs. colonization were associated with slight 
increases in the point estimates of the aHR of 3.23 (95% CI 1.82–5.89, p<0.0001), and 3.64 
(95% CI 1.80–7.27, P<0.001). The aHR for the association between UTI vs. colonization 
remained similar at 0.63 (95% CI 0.24–1.46, p=0.28).
 Other outcomes
Patients with BSI and pneumonia had significantly longer durations of hospitalization when 
compared to colonized controls (Table 2); BSI and pneumonia were associated with an 
increased median total length of stay of 5 days (p<0.01) and 10 days (p<0.0001) 
respectively. The median length of stay after first positive culture was also significantly 
prolonged in patients with BSI or pneumonia; by 2 days (p=0.03) and 3 days (p<0.01), 
respectively. In contrast, the length of stay in patients with UTI vs. colonization was similar; 
10 days vs. 9 days for median total length of stay and 7 days vs. 7 days for the median post-
culture length of stay (Table 2). Patients with BSI as well as those patients with pneumonia 
were more likely to be critically ill at the time of first positive culture when compared to 
controls. In the BSI cohort, 56% of patients as compared to 22% in controls were critically 
ill (p<0.0001). In the pneumonia cohort, this difference was even more pronounced; 86% of 
patients with CRKp pneumonia were critically ill (p<0.0001). No significant difference in 
critical illness rates were observed between patients with UTI and colonization.
 Discussion
A novel method of estimating excess mortality in patients with infections caused by MDR-O 
is described here. Using this method and after adjustment for confounding variables, patients 
with CRKp pneumonia died at more than 3 times the rate of similar patients with CRKp 
colonization. This effect size is consistent with the known severity of pneumonia in 
hospitalized patients caused by multidrug-resistant organisms (MDR-O) [22–24]. Patients 
with CRKp BSI died at more than twice the rate compared to those with CRKp colonization. 
This is also consistent with previous studies on all-cause mortality in patients with CRKp 
BSI [5–9]. In addition to mortality risk, CRKp pneumonia and BSI were also associated 
with increases in both total and post-culture length of hospitalization. Increased length of 
stay is important for several reasons; it is associated with increased health care costs, 
increased risk for other hospital-acquired infections and complications, and increased spread 
of CRE to other vulnerable patients.
In this study, the excess hospital mortality rates in three cohorts of patients with CRKp 
infections were estimated by comparing them to patients with urinary CRKp colonization. 
This is a novel way of evaluating mortality that takes into account measured and unmeasured 
risk factors that are associated with CRKp colonization in hospitalized patients. Risk factors 
for CRKp colonization include exposure to acute care and long-term care settings, 
antibiotics, indwelling devices, as well as certain comorbid conditions [25–27]. Reported 
risk factors for subsequent CRKp infection in colonized patients included ICU admission, 
central venous catheters, receipt of antibiotics, diabetes mellitus, abdominal invasive 
procedures, and chemotherapy or radiation therapy [28, 29]. As outlined by Safdar and Maki 
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in 2002, risk factors for colonization with MDR-O tend to overlap and therefore co-
colonization of CRKp with other MDR-O is often found [30, 31]. To some extent these risk 
factors can be measured and controlled for, but a cohort of patients without MDR-O will 
always be different in a variety of ways from a cohort with MDR-O. Therefore, the current 
approach was chosen to estimate as closely as possible the impact of getting a specific 
infection caused by CRKp in a relatively homogeneous population. Patients with enteral 
CRKp colonization form the background population from whom it is postulated that both 
cases and controls arose in this study.
In contrast to patients with pneumonia and BSI, patients with CRKp UTI had no excess 
mortality when compared to colonized patients. This is a good example that simply 
examining crude mortality rates may be misleading. An important limitation in this context 
is that the diagnosis of UTI is notoriously difficult. We used standardized definitions which 
nonetheless may misclassify patients. This misclassification may have contributed to the 
lack of difference in mortality between patients with UTI and urinary colonization. However, 
the data presented here are biologically plausible and consistent with previous reports [11, 
13]. Another limitation of the study is that patients were not followed after their discharge 
from the hospital. This could potentially result in informative censoring which could have 
biased the results of the Cox models. In addition, longer term outcomes are of great interest 
in this population and deserve further study.
In summary, CRKp pneumonia and CRKp BSI are associated with large mortality risks in 
hospitalized patients. CRKp UTI, on the other hand, is not associated with excess mortality. 
The quantification of these risks may help guide future interventions and hopefully motivate 
interventional studies to decrease both the risk of CRE colonization and infection.
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Figure 1. Time-to-hospital-mortality compared between patients infected vs. colonized with 
carbapenem-resistant K. pneumoniae (CRKp)
Kaplan-Meier curves are shown and groups were compared using log-rank testing. Data 
were censored at the time of hospital discharge. A. Time-to-hospital-mortality in patients 
with CRKp bloodstream infection. B. Time-to-hospital-mortality in patients with CRKp 
pneumonia. C. Time-to-hospital-mortality in patients with CRKp urinary tract infection.
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